AMLX - Amylyx Pharmaceuticals, Inc.
17.59
0.020 0.114%
Share volume: 814,579
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$17.57
0.02
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-08-2024 | 11-07-2024 | 03-04-2025 | 05-08-2025 | 11-06-2025 | 03-03-2026 | |
| Total revenue | 88.643 M | -1.023 M | 416.000 K | -665.000 K | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 5.945 M | 8.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 82.698 M | -1.031 M | 416.000 K | -665.000 K | 0.000 | 0.000 | 0.000 | |
| -101.25% | 140.35% | -259.86% | 100.00% | nan% | nan% | |||
| Operating expenses | 94.367 M | 44.994 M | 75.268 M | 39.989 M | 37.803 M | 36.027 M | 36.604 M | |
| Selling general and admin | 57.759 M | 21.647 M | 17.828 M | 17.097 M | 15.684 M | 16.172 M | 15.391 M | |
| Research and development | 36.608 M | 23.347 M | 57.440 M | 22.892 M | 22.119 M | 19.855 M | 21.213 M | |
| Total expenses | 204.828 M | 75.255 M | 76.077 M | 39.989 M | 37.803 M | 36.027 M | 36.604 M | |
| -63.26% | 1.09% | -47.44% | -5.47% | -4.70% | 1.60% | |||
| Operating income | -122.130 M | -76.286 M | -75.661 M | -40.654 M | -37.803 M | -36.027 M | -36.604 M | |
| Ebit | -122.877 M | -76.769 M | -75.802 M | -40.497 M | -38.138 M | -36.207 M | -36.243 M | |
| Pretax income | -118.551 M | -72.700 M | -72.704 M | -38.181 M | -35.907 M | -34.386 M | -32.953 M | |
| -38.68% | 0.01% | -47.48% | -5.96% | -4.24% | -4.17% | |||
| Income tax | 242.000 K | 0.000 | 0.000 | -635.000 K | 0.000 | 0.000 | 46.000 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -118.793 M | -72.700 M | -72.704 M | -37.546 M | -35.907 M | -34.386 M | -32.999 M | |
| 38.80% | -0.01% | 48.36% | 4.37% | 4.24% | 4.03% |